Multiple Sclerosis Clinical Trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Background Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many

myelopathies
nervous
brain mri
prednisone
methylprednisolone
  • 20 views
  • 11 May, 2022
  • 1 location
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and

ocrelizumab
relapsing multiple sclerosis
brain mri
disease or disorder
  • 9 views
  • 10 May, 2022
  • 10 locations
Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis? (FatSEP)

Chronic fatigue is the most common and debilitating symptom in multiple sclerosis patients. This chronic fatigue affects their quality of life by decreasing their capacity to perform simple

Accepts healthy volunteers
fatigue
MRI
  • 20 views
  • 11 May, 2022
  • 1 location
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (ENLIGHTEN)

This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years. All subjects will receive orally administered ozanimod HCl 1 mg. The primary efficacy endpoint is …

relapsing multiple sclerosis
  • 278 views
  • 18 May, 2022
  • 54 locations
Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis

The proposed trial is a prospective, randomized (1:1) trial plan examining whether more routine and frequent measurement of Patient Related Outcome Measures (PROMs) in the care of patients with MS improves patient depression and anxiety outcomes in addition to patient care satisfaction. The investigators plan to randomize people with MS …

anxiety
depressed mood
  • 0 views
  • 05 May, 2022
  • 1 location
Profile of Adherence to Therapy and Interventions to Promote Adherence in MS

implementation and persistence and it is estimated to be around 50% in various chronic illnesses, including Multiple Sclerosis (MS). MS patients who fail to properly adhere to their DMTs regimen may be at

chronic disease
nervous
disease or disorder
  • 7 views
  • 09 Apr, 2022
  • 1 location
Adderall XR and Cognitive Impairment in MS

This 12 week randomized placebo-controlled study will compare the effects of 10 mg and 20 mg of a mixed amphetamine salt, extended release medication (trade name Adderall XR) to placebo on objective measures of processing speed and memory, as well as on self-reported measures of cognition and quality of life. …

corticosteroids
  • 2447 views
  • 19 Apr, 2022
  • 3 locations
RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS (RAM-MS)

This study is a randomized multicentre, multinational, treatment interventional study of RRMS patients with breakthrough inflammatory disease activity in spite of ongoing standard immunomodulatory medication. The study has two treatment arms; arm A: HSCT (hematopoietic stem cell transplantation) and arm B: alemtuzumab, a registered immunomodulatory treatment of RRMS. A pre-planned …

teriflunomide
glatiramer acetate
fingolimod
interferon
cyclophosphamide
  • 35 views
  • 09 Apr, 2022
  • 7 locations
The Use of Technology to Improve MS Clinical Trials and Patient Care

Many patients with multiple sclerosis (MS) experience "relapses" of disease activity during which they have increased numbness, weakness, visual problems, or other symptoms. If a person with MS

teriflunomide
glatiramer acetate
fingolimod
interferon
disease or disorder
  • 25 views
  • 13 May, 2022
  • 1 location
Tolebrutinib, a Brain-penetrant Bruton s Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Background Some multiple sclerosis (MS) lesions stay inflamed for very long periods of time. This type of inflammation is not affected by any MS medications. These

rituximab
MRI
ocrelizumab
  • 0 views
  • 09 May, 2022
  • 1 location